CardInnov: “Research targeting development of innovative therapeutic strategies in cardiovascular disease”
Aim of the call
Proposals must present research that addresses one or both of the following topics:
1) Repair and/or regeneration of the heart and/or the blood vessels
The proposals should focus on:
- The identification of integrative approach, clinically relevant, based on molecular and cellular levels and/or the link between these two levels. Poorly known mechanisms should be the focus of the proposal e.g. (but not limited to) the inflammatory reaction, the amyloid accumulation, endogenous mechanisms of repair, linked to thromboembolism and/or related to macrovascular compartment and autonomous nervous system.
- And/or the development of cell and non-cell-based approaches in combination with bioactive biomaterials/ bioengineered patches or grafts.
2) Chronic heart failure and atrial fibrillation
The proposals should focus on the development of treatment strategies that can reverse the pathophysiology responsible for chronic heart failure (especially with preserved ejection fraction), atrial fibrillation and/or the both diseases. The therapeutic strategies should take into account patient comorbidities and their potential treatment.
Exclusion:
For both topics, research on cell therapy is strictly restricted to novel and innovative approaches.
Call Calendar
| Call Pre-announcement | 7 November 2022 |
| Announcement of the Call | 7 December 2022 |
| Submission system will be open | 9 December 2022 |
| Deadline for the submission of Pre-proposals | 7 February 2023 (16:00, CET) |
| Deadline for the submission of invited Full-proposals | 15 June 2023 (16:00, CET) |
General conditions for application
The duration of the projects will be 36 months.
Joint research proposals may be submitted by applicants belonging to one of the following categories (according to national/regional regulations; certain categories may not be eligible for funding by a specific funding organisation, please see Annex I of the call text):
- A. Academia – research teams working in universities, other higher education institutions or research institutes.
- B. Clinical/public health sector – research teams working in hospitals/public health and/or other health care settings and health organisations.
- C. Enterprises – private companies of all sizes.
- and D. Operational stakeholders – e.g. patient advocacy organisations, municipalities and local governments, local/national NGO’s. In line with the concept of RRI, operational stakeholders should be in a position to provide useful knowledge to the consortium, ensure the consortium’s research is useful and translatable to their (or other) organizational contexts, and/or influence decision making or create change within their organisations. Operational stakeholders should be engaged in the research process from conception of the study to dissemination.
Size of the consortium
The number of participants and their research contribution should be appropriate for the aims of the transnational research project and be reasonably balanced in terms of international participation. Each transnational collaborative project should represent the critical mass to achieve ambitious scientific goals and should clearly demonstrate an added value from working together.
Only transnational projects will be funded. The following conditions apply to the composition of consortia:
- Minimum of three eligible and a maximum of five eligible partners from at least three different countries participating in the call.
- The maximum number of eligible partners can be increased up to six or seven if they include one or two partners, respectively, from the following participating countries: Latvia, Lithuania, Romania, Slovakia, Turkey.
- No more than two eligible partners from the same country participating in the call will be accepted within one consortium.
- Maximum of two collaborators per consortium. Collaborators are self-funded partners: i.e. partners that do not request funds in this Joint Transnational Call provided by one of the participating funding organisations (i.e. partners from non-funding countries or partners which are not fundable according to national/regional regulations of the participating funding organisations).
There will be a two-step submission and evaluation procedure for joint applications, i.e. pre-proposals and full proposals, and the full proposal review process will be complemented by a rebuttal stage. For both submission steps, one joint proposal document (in English) shall be prepared by the partners of a joint transnational proposal and must be submitted on the electronic submission system by the project coordinator.
Information & Application
| Call Text | |
| Pre-proposal application form | |
| Submission Platform | |
| Infoday Video (2022/12/13) | |
| Facts and Figures |
Participating countries/regions and respective funding organisations
Facts and Figures
Results of the ERA4Health CArdInnov Call 2023Events related to the call
Funded Projects of the call
| AmnioSMART | Defining the ideal human Amniotic progenitor Secretome forMulation for future cArdioprotective paRacrine Therapy | More |
| DETECIT | Develop a nanotracer for early diagnosis of cardiac amyloidosis and disease monitoring | More |
| Ener-LIGHT | Energizing the failing heart | More |
| GANDHI | O-GlcNAcase Inhibition in Acute Decompensated Heart Failure | More |
| HF4HF | Cardiac metabolic reprogramming by a nutritional intervention: High Fat diet for Heart Failure | More |
| HFpEF-DIVA | Diverging HFpEF Phenotypes : patient-tailoreD targeting of anti-Inflammatory pathways to limit Ventricular and Atrial remodelling | More |
| ID-PRESERVED | A Blueprint of Inflammatory Drivers of Heart Failure with Preserved Ejection Fraction | More |
| MARGINALIZE-MI | Immunotherapy targeting marginal zone B lymphocytes to promote cardiac repair after acute myocardial infarction | More |
| MASTer | Mast cells as effectors in hemorrhage and acute cardiovascular diseases | More |
| NeuroImmunMetHF | Understanding the role of NeuroImmunoMetabolic axis in development of HFpEF | More |
| PERSUADE | PERsistent atrial fibrillation: SUbstrate tArgeteD stratEgy (PERSUADE) | More |
| RECREATE | non-coding Rna thErapeutics to elicit Cardiac Regeneration in ischEmic heArT disEase | More |
| ReNewAthero | Self-Antigen expressing RNA therapy for atherosclerosis | More |
| RepairQ | Understanding and repairing GNAQ-mutant blood vessels | More |
| RESCUE | Bridging the gap between cardiac and vascular regeneration | More |
| RESPIN-VAR | REstoring balance: Specialized Proresolvin mediators for resolution of INflammation and VAscular Repair in humans at high cardiovascular risk | More |
| SK4BLOCK-AFHF | SK4 K+ channel blockers: targeting calmodulin-PIP2 interface as new mechanism-based treatment of atrial fibrillation and heart failure | More |